Pulmonary Cell News Volume 12.40 | Oct 12 2023

October 12, 2023

2023-10-12 | PULCN 12.40

Pulmonary Cell News by STEMCELL Technologies

Vol. 12.40 – 12 October, 2023

TOP STORY

Eosinophils Promote Pulmonary Matrix Destruction and Emphysema via Cathepsin L

Investigators employed single-cell RNA sequencing to identify eosinophil subgroups in mouse models of asthma and emphysema, followed by functional analyses of these subgroups.
[Signal Transduction And Targeted Therapy]

Full Article

PUBLICATIONSRanked by the impact factor of the journal

Paroxetine Protects against Bleomycin-Induced Pulmonary Fibrosis by Blocking GRK2/Smad3 Pathway

Scientists investigated the effects of paroxetine on pulmonary fibrosis in C57/BL6 caused by bleomycin as well as on the activation of murine primary lung fibroblasts stimulated with TGF-β1.
[Aging]

Full Article

Buyang Huanwu Decoction Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats by Attenuating the Apoptosis of Alveolar Type II Epithelial Cells Mediated by Endoplasmic Reticulum Stress

Investigators explored the therapeutic effects and underlying mechanisms of Buyang Huanwu decoction on bleomycin-induced pulmonary fibrosis in rats.
[Journal Of Ethnopharmacology]

Abstract Graphical Abstract

LncRNA PVT1 Induces Apoptosis and Inflammatory Response of Bronchial Epithelial Cells by Regulating miR-30b-5p/BCL2L11 Axis in COPD

Plasmacytoma variant translocation 1 (PVT1) enhanced apoptosis and inflammation of 16HBE cells under cigarette smoke extract stimulation by modulating miR-30b-5p/BCL2L11 axis.
[Genes And Environment]

Full Article

LUNG CANCER

Signature-Driven Repurposing of Midostaurin for Combination with MEK1/2 and KRASG12C Inhibitors in Lung Cancer

Scientists provided a rational framework for selecting drugs entering combinatorial strategies and unveils MEK1/2- and KRASG12C-based therapies for lung cancer.
[Nature Communications]

Full Article

PTPN23 Ubiquitination by WDR4 Suppresses EGFR and C-MET Degradation to Define a Lung Cancer Therapeutic Target

Using an unbiased ubiquitylome analysis, researchers uncovered PTPN23, a component of the ESCRT complex, as a substrate of WDR4-based ubiquitin ligase.
[Cell Death & Disease]

Full Article

SYVN1-Mediated Ubiquitylation Directs Localization of MCT4 in the Plasma Membrane to Promote the Progression of Lung Adenocarcinoma

Taking advantage of human lung adenocarcinoma cells, researchers revealed that monocarboxylate transporter 4 (MCT4) can be polyubiquitylated in a nonproteolytic manner by SYVN1 E3 ubiquitin ligase.
[Cell Death & Disease]

Full Article

A Novel Selective ERK1/2 Inhibitor, Laxiflorin B, Targets EGFR Mutation Subtypes in Non-Small-Cell Lung Cancer

Scientists identified a potential novel covalent extracellular regulated protein kinase (ERK) inhibitor, Laxiflorin B, which was a herbal compound with anticancer activity.
[Acta Pharmacologica Sinica]

Abstract

NARFL Deficiency Caused Mitochondrial Dysfunction in Lung Cancer Cells by HIF-1α–DNMT1 Axis

Knockdown assay was performed in A549 and H1299 cells. The protein levels of HIF-1α and DNMT1 were measured, and then Complex I activity, mtDNA copy numbers, and mRNA levels of mtND genes were determined.
[Scientific Reports]

Full Article

Stay current with COVID-19 research. Read Immunology of Infectious Disease News now.

REVIEWS

Lung Organoid on a Chip: A New Ensemble Model for Preclinical Studies

The authors summarize the key components and previous biomedical studies conducted on lung organoids and lung-on-a-chip models and introduce potential future applications.
[International Journal Of Stem Cells]

Abstract

INDUSTRY AND POLICY NEWS

Janssen Submits Application to the European Medicines Agency for RYBREVANT^®▼ (Amivantamab) in Combination with Chemotherapy for the First-Line Treatment of Adult Patients with Advanced Non-Small Cell Lung Cancer with Activating EGFR Exon 20 Insertion Mutations

“People living with advanced or metastatic NSCLC with activating EGFR exon 20 insertion mutations generally face a poor survival probability, and new treatment options are urgently needed from the very first line of therapy,” said Martin Vogel, EMEA Therapeutic Area Lead Oncology, Janssen-Cilag GmbH.
[The Janssen Pharmaceutical Companies of Johnson & Johnson]

Press Release

FEATURED EVENT

Pulmonary Cell News Volume 12.40 | Oct 12 2023

Eosinophils Promote Pulmonary Matrix Destruction and Emphysema via Cathepsin L

Paroxetine Protects against Bleomycin-Induced Pulmonary Fibrosis by Blocking GRK2/Smad3 Pathway

Buyang Huanwu Decoction Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats by Attenuating the Apoptosis of Alveolar Type II Epithelial Cells Mediated by Endoplasmic Reticulum Stress

LncRNA PVT1 Induces Apoptosis and Inflammatory Response of Bronchial Epithelial Cells by Regulating miR-30b-5p/BCL2L11 Axis in COPD

Signature-Driven Repurposing of Midostaurin for Combination with MEK1/2 and KRASG12C Inhibitors in Lung Cancer

PTPN23 Ubiquitination by WDR4 Suppresses EGFR and C-MET Degradation to Define a Lung Cancer Therapeutic Target

SYVN1-Mediated Ubiquitylation Directs Localization of MCT4 in the Plasma Membrane to Promote the Progression of Lung Adenocarcinoma

A Novel Selective ERK1/2 Inhibitor, Laxiflorin B, Targets EGFR Mutation Subtypes in Non-Small-Cell Lung Cancer

NARFL Deficiency Caused Mitochondrial Dysfunction in Lung Cancer Cells by HIF-1α–DNMT1 Axis

Lung Organoid on a Chip: A New Ensemble Model for Preclinical Studies

Janssen Submits Application to the European Medicines Agency for RYBREVANT^®▼ (Amivantamab) in Combination with Chemotherapy for the First-Line Treatment of Adult Patients with Advanced Non-Small Cell Lung Cancer with Activating EGFR Exon 20 Insertion Mutations

Single Cell View 3D Genome Architecture

> See All Events

Postdoctoral Fellow – Airway Inflammation

Research Positions – Pluripotent Stem Cell, Lung Differentiation, and Genomics Project

Academic Physician – Sleep Medicine and/or COPD

Assistant/Associate Professor – Pulmonary Medicine

Postdoctoral Position – Mucosal Immunity

> See All Jobs